Analysts think TBPH stock price could increase by 37%
Feb 10, 2025, 12:25 PM
0.00%
What does TBPH do
Theravance Biopharma, based in Grand Cayman, focuses on developing respiratory medicines and has 99 employees; its key product, YUPELRI, treats COPD. The company is also developing Ampreloxetine for neurogenic orthostatic hypotension and TD-8954 for gastrointestinal motility disorders.
6 analysts think TBPH stock price will increase by 37.10%. The current median analyst target is $12.75 compared to a current stock price of $9.30. The lowest analysts target is $9.09 and the highest analyst target is $22.05.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.